- RetinalGenix Technologies (OTCQB:RTGN) partners with LabCorp to expand genetic and retinal health screening across the U.S.
- The partnership aims to make early disease detection more accessible and cost-effective.
- Efforts are underway to establish CPT codes to reduce healthcare expenses and improve patient access.
RetinalGenix Technologies (OTCQB:RTGN) has entered into a significant collaboration with LabCorp, one of the leading laboratory service providers, to introduce its innovative DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This initiative will allow patients to undergo genetic testing and high-resolution retinal imaging at LabCorp locations nationwide.
The platform employs proprietary algorithms to analyze blood, tears, nasal secretions, and saliva, correlating genetic and retinal biomarkers for early disease detection. This service is set to reduce dependency on costly diagnostic methods such as MRIs and CT scans, offering a more accessible and cost-effective alternative for health screenings.
RetinalGenix is actively working with regulatory bodies to establish CPT codes, which could significantly lower healthcare costs and enhance patient access to necessary medical evaluations. The company plans to roll out high-resolution retinal imaging services as an additional offering at various locations soon.
By maintaining patient privacy, the service ensures that health records remain anonymous and confidential, with results securely provided to patients upon payment validation at selected LabCorp centers. This partnership marks a step forward in integrating advanced genetic screening and imaging technologies for improved disease detection and patient outcomes.
